Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Immunogenicity and Safety of Vaccination Against Tick Borne Encephalitis (TBE) in Patients Living With Multiple Sclerosis (MS) (MS and TBE vac)

17. November 2026 aktualisiert von: Insel Gruppe AG, University Hospital Bern

This is a monocenter, prospective cohort study. The study investigates the response of patients living with multiple sclerosis (MS) to vaccination against tick-borne viral encephalitis (TBE).

The prevalence of TBE has increased significantly in Switzerland over the past two decades. Whereas previously only the lowland regions of northern Switzerland and the Aare Valley were considered areas where TBE vaccination was indicated, the disease is now endemic throughout Switzerland (except for Ticino). Since TBE specifically affects the nervous system, there is a clear indication for vaccination, particularly for people whose nervous system is already compromised.

MS is the most common neurological autoimmune disease among young adults in northern latitudes. It is a progressive disease characterized by a gradual deterioration of neurological functions. The course of the disease can be slowed through immunomodulatory therapies. However, these therapies also lead to a certain degree of immunosuppression, which may reduce the immune response to vaccinations. At the same time, some people with MS experience fear or scepticism towards vaccinations, as infections often lead to a worsening of symptoms or can trigger a relapse. Since vaccinations mimic an infection to some extent, this concern is sometimes transferred to vaccinations as well.

The study hypothesizes that the TBE vaccine in people living with MS on non-B-cell depleting treatment shows adequate immunogenicity.

Moreover, the study will assess the safety of TBE vaccination.

Studienübersicht

Status

Rekrutierung

Bedingungen

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

50

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

The investigators target a sample size of 50 people living with MS with stable RRMS (no evidence of disease activity -NEDA-3 status - as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI) for ≥ 1 year prior to inclusion into the study and treated with non-B-cell depleting therapies for at least 6 months in monotherapy.

In order to have a homogenous and stable patient population, the investigators decided to include only patients without evidence of disease activity for at least 1 year prior to inclusion. Considering the latter the investigators classify any disease reactivation during the period of 42 days (+/- 7days) after the first dose / booster dose as related to the intervention (vaccination).

Beschreibung

Inclusion Criteria

  • Adult (≥ 18 years old)

  • Suspected neuroimmunological disorder with CNS affection

    • including suspicion of Multiple Sclerosis (MS)
    • Diagnosed Multiple Sclerosis (MS)
    • Clinically Isolated Syndrome
    • Radiologically Isolated Syndrome
  • stable RRMS - defined as no evidence of disease activity-NEDA-3 status-as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI for ≥ 1 year prior to inclusion

  • treated with non-B-cell depleting therapies for at least 6 months in monotherapy

  • TBE vaccine:

    • never been vaccinated against TBE or
    • clinical indication for booster vaccination (person living with MS and has had primary series of 3 vaccines of which the last one was ≥ 10 years ago)
  • Provided written informed consent

Exclusion Criteria

  • Any B-cell depleting therapies in last 12 months prior to recruitment
  • Any other vaccination in last 2 months prior to recruitment
  • Any foreseeable and necessary other vaccination up to 42 days post dose 1
  • Immunoglobulin-Infusion (intravenous or subcutaneous, IVIG or SCIG) in the last 4 months prior to the drawing of study samples

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Primary vaccination series or Booser against TBE in patients with MS

According to Swiss guidelines, patients with MS will receive the primary vaccination series (3 doses) against TBE (if they have never been vaccinated) or a TBE booster (if they have already received the primary vaccination series and their last vaccination was ≥ 10 years ago).

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Primary immunogenicity endpoint
Zeitfenster: 42 days post dose 1

Change in antibody concentration (GMC) from baseline to day 42 post dose 1 as measured by ELISA

42 days post dose 1

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Immunogenicity endpoint
Zeitfenster: 42 days post dose 1

Change in antibody titers as measured by serum neutralizing test (SNT) from baseline to day 42 (post dose 1)

42 days post dose 1
Immunogenicity endpoint
Zeitfenster: 7 months post dose 1 or 6 months post booster dose

Change in antibody titers as measured by ELISA from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose.

7 months post dose 1 or 6 months post booster dose
Immunogenicity endpoint
Zeitfenster: 7 months post dose 1 or 6 months post booster dose

Change in antibody titers as measured by SNT from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose.

7 months post dose 1 or 6 months post booster dose
Immunogenicity endpoint
Zeitfenster: at each time point (7 months)

Seropositivity as measured by ELISA . Seropositivity is defined as IgG antibody concentration >150 U/ml for ELISA.

at each time point (7 months)
Immunogenicity endpoint
Zeitfenster: at each time point (7 months)

Seropositivity as measured by SNT at each time point. Seropositivity is defined as antibody titer >1:10 for SNT.

at each time point (7 months)
Safety endpoint
Zeitfenster: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Incidence of MS-relapses - defined clinically, according to clinical expert judgement, by the presence of MS-typical symptoms with objectifiable findings lasting more than 24 hours, without fever or infection.

42 (+/-7d) post dose 1
Safety endpoint
Zeitfenster: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Activity in cerebral MRI scan (new or enlarging lesions or gadolinium uptake)

42 (+/-7d) post dose 1
Safety endpoint
Zeitfenster: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Neurological assessment (EDSS)

42 (+/-7d) post dose 1
Safety endpoint
Zeitfenster: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Multivariable blood biomarker based scores for MS disease activity (MSDA) and disease pathways (Octave Bioscience, USA)

42 (+/-7d) post dose 1
Safety endpoint
Zeitfenster: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Vaccine reactogenicity (solicited and unsolicited local and systemic vaccine reactions)

42 (+/-7d) post dose 1

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

22. April 2026

Primärer Abschluss (Geschätzt)

31. Mai 2027

Studienabschluss (Geschätzt)

31. Mai 2027

Studienanmeldedaten

Zuerst eingereicht

28. August 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

17. November 2026

Zuerst gepostet (Tatsächlich)

19. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

19. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. November 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren